Jump to content

Carotenoid complex

Add links
From Wikipedia, the free encyclopedia

Carotenoid complexes are physical associations of carotenoids with other molecules.

Carotenoids and lipids

[edit]

Carotenoids are hydrophobic molecules that are usually coupled with lipids to form complexes.

Role in Biology

[edit]

Carotenoids help living species to adapt to environmental stresses, in particular temperature variations by making complexes with lipids.[1]

Their role in supporting photosynthesis is also well documented.[2][3]

Since plants, or microorganisms such algae, fungi and bacteria, have exposure to a much higher day-night, seasonal or other environmental temperature variability than animals, it is not surprising that the level of carotenoids in their tissues is 103 – 106 higher than in animals.[4][5] Ectothermic animals, which do not have their own mechanism to control body temperature, rely more on accumulation of ingested carotenoids than endotherms, which can maintain their thermal homeostasis. It is not surprising that in tissues of fish or reptiles, carotenoid concentration could be from 10 to 100 fold higher than in mammalians.[6][7]

Different lipids have different crystalline structures, which determine their viscosity and heat or thermal conductivity. This in turn affects membrane signaling and transport, energy production and other processes essential for cellular metabolism and functions.[8][9] For a plant cell to synthesize 1 molecule of a carotenoid, which can change the viscosity and thermal energy conductivity of 10,000 or even 100,000 molecules of lipids, would be much faster and more economic than to activate a lipid replacement process, which would involve a few hundred or thousand more new lipid molecules to be synthesized.

In animals and humans, carotenoid lipid complexes play an additional role to temperature adaptation role, or thermogenesis. They are able to control lipid droplet formation, LD, and mitochondrial activation/respiration, blood plasma lipoprotein oxygen transport, control of and tissue oxygenation.[10][11][12]

Role in nutrition

[edit]

Vegetable oils

[edit]

Oils used today as a food ingredient or for cooking are highly refined or ultra-processed products, which contribute, alongside refined sugars to the global obesity pandemic.[13][14] Removal of carotenoids from pressed raw oils, together with other “impurities”, significantly changes their physical and nutritional properties, making oils faster to digest, hence increases calorie absorption and postprandial lipidaemia.

L-tug technology reintroduces carotenoids back to refined oils, making complexes with them and restoring their natural health beneficial properties and reducing their digestion rate and lipid and calorie absorption.[15][16][17][1]

Animal fats

[edit]

Green grass grazed cows produce carotenoid rich milk lipid globules, which have fat with a lower digestion rate than those fed with carotenoid depleted hay or cattle feed. Since green grass is not available in many countries throughout the year, an alternative is L-tug technology. This improves the nutritional properties of dairy or other animal fat by forming complexes with carotenoids which are naturally present in grass or other plants that animals eat.[17]

Lycosome

[edit]

The name lycosome (not to be confused with lysosome) originated from the first group of such complexes which used lycopene, one of the carotenoid molecules.

Improvement in bioavailability

[edit]

Absorption

[edit]

Formation of these complexes could be useful in improving absorption and efficacy of those vitamin, nutraceutical and pharmaceutical molecules which have reduced bioavailability due to their sensitivity to stomach acidity and/or digestive enzymes. Carotenoids can provide protection from such factors and this would enable more bioactive molecules to reach points of their absorption in an unmodified form which can improve pharmacokinetics and efficacy of these molecules.

Use of lycosomes can also reduce administered doses, hence the cost of the products, without reduction of their therapeutic effect.[11][12]

Tissue bioavailability

[edit]

Absorption of bioactive molecules is essential but not sufficient to achieve their supplementation or therapeutic objectives. They need to be available from blood circulation to body tissues. Hydrophobic molecules cannot be transported in blood by themselves but only as a part of lipoprotein particles. Their incorporation into these particles happens firstly in enterocytes during chylomicron formation and then, secondly, during lipoprotein assembly in the liver.[18][19]

If lipoprotein particles get modified, for example during peroxidation, their ability to transport hydrophobic molecules is reduced. The presence of carotenoids can protect lipoproteins from peroxidation[20][21] and improve their transportation role. Therefore, complexes of carotenoids with hydrophobic bioactive molecules can improve not only their absorption but also tissue bioavailability.

Carotenoid incorporation into lipoproteins

[edit]

Carotenoids enter lipoprotein structures during their assembly.[22][23]

Phospholipids, in particular phosphatidylcholine, play a critical role in this process as scaffolding for lipids, proteins and other hydrophobic molecules.[24][25] If there is a deficiency in phospholipids or they get oxidized, which happen, alongside other components of lipoproteins, the assembly of these particles gets impaired. As a result of this, despite sufficient intake of carotenoids, their concentration in blood and tissue delivery would be reduced.

This oxidation could be caused by tissue steatosis and hypoxia as a consequence of inflammation in fatty liver, NASH or NAFLD, in obese people or even, on a subclinical level, in the elderly.[26][27]

Targeted delivery

[edit]

The spectrum of carotenoids varies in different organs and different tissues. For example, lycopene can be found in most human body tissues but preferably accumulated in the liver, adrenal glands and male reproductive system.[28][29] Another carotenoid, lutein is also found in different organs but it is one of the most preferred carotenoids of the brain and its retina and of the ovaries.[30][31]

This different affinity of different carotenoids to different organs can be used for more targeted delivery of hydrophobic bioactive molecules. After absorption of components of carotenoid complexes with these molecules, they all will be co-incorporated into lipoprotein particles assembled in enterocytes, or in the liver. Carotenoids with preferential affinity to different organs may serve as a vector for the whole particles and for more targeted delivery of their “cargo” of bioactive molecules.

Inclusion of carotenoids into complexes with hydrophobic bioactive molecules, which have metabolic or therapeutic targets in particular organs, can reduce their concentration in other organs. This on the one hand reduces potential side effects of these molecules in non-targeted organs, and on the other reduces administered doses, hence the cost of the products, without reduction of their therapeutic effect.

New mode of action – tissue oxygenation

[edit]

Carotenoids, in their complexes with other bioactive molecules, can not only improve their bioavailability and facilitate targeted delivery, but themselves have important biological and therapeutic properties. Since they can protect lipid structures from oxidative damage, they can protect their functions as well. One of the important roles of plasma lipoproteins is their ability to transport molecular oxygen into interstitial or intracellular fluid.[11][32]

Reduction of the oxygen carrying capacity of these particles leads to a reduction in oxygen supply to tissues and in severe cases contributes to development of tissue hypoxia. Carotenoids, by helping to maintain the crystalline structure not only of plasma lipoproteins but also cellular membranes and intracellular lipid droplets, can support their oxygen carrying / holding capacity. This could be important for aerobic respiration and mitochondrial ATP synthesis on the cellular level and as a part of anti-hypoxia treatment on the tissue and organ level.

Therefore, formation of complexes of carotenoids with bioactive molecules may not only improve their own efficacy, but add a new tissue oxygenation modality, which can synergistically benefit supplementation or therapeutic objectives.

LycoD3

[edit]

LycoD3 is a complex of lycopene with vitamin D3, or cholecalciferol. This vitamin is very important not only for the control of calcium metabolism but also for the support of immune system and inflammation.[33][34][35] Therefore, treatment of D3 deficiencies is an important health issue. LycoD3 aims to overcome metabolic difficulties with D3 supplements.

Supplementation challenges

[edit]

Not all D3 deficiencies can be effectively supplemented or treated with vitamin D3 on its own. Older people or those who have fatty liver or metabolic syndrome have a declined ability to absorb, transport and activate vitamin D3.[36][37] In addition, in overweight or obese persons an excessive adipose tissue can sequester D3 from the circulation and reduce its access to other tissues.[38][39]

Liver – gut activation

[edit]

For vitamin D3 to perform its regulatory roles, it needs to be converted into biologically active metabolites. This activation by a hydroxylation cascade begins in two locations in the body, the liver by the cytochrome P450 system, and the gut by its microbiome.[40][41] The lycopene and phosphatidylcholine complex with vitamin D3 is able not only to protect it from stomach acidity but also to facilitate its delivery to the locations where it can be activated.

Lycopene was chosen for a number of reasons. Firstly, it is relatively more resistant to acidic degradation than other carotenoids most used in humans. Secondly, since after oral administration absorbed vitamin D3 is transported by chylomicrons, co-incorporated lycopene, which has an affinity to the liver, would facilitate D3 delivery to that organ where it can be hydroxylated. The third reason is that lycopene is able not only support vitamin D3 transition and activation in the gut but also activate microbiome immunity there, which would be synergetic to D3 efficacy.[42]

Clinically validated carotenoid complexes with nutraceutical and pharmaceutical molecules

[edit]

All of the complexes listed below, apart from superior pharmacokinetics and/or pharmacodynamics over complex-free bioactives, have the additional ability to reduce blood markers of oxidative and inflammatory damage and anti-hypoxic efficacy.

Lycopene – phosphatidylcholine – anti-inflammatory whey protein isolate.[11]

Lycopene – phosphatidylcholine – trans-resveratrol: promotes foot ulcer regeneration in patients with diabetes 2.[43]

Diabetic foot ulcer images before and after 60-day trans-resveratrol lycosome or placebo treatment.[43]

Lycopene – phosphatidylcholine - soy isoflavones: reduces insulin resistance on a par with metformin[44]

Lycopene – phosphatidylcholine – simvastatin[45]

LycoD3, Lycopene – phosphatidylcholine – vitamin D3: 6 fold improvement in pharmacokinetics of activated 25(OH)D3 over the complex-free D3

Lycopene – phosphatidylcholine – Coenzyme Q10: 7 fold improvement in pharmacokinetics over the complex-free Q10[45]

Lycopene – Anthocyanins: 3 fold improvement in pharmacokinetics over the complex-free anthocyanins

Lutein – Anthocyanins: 7 fold improvement in pharmacokinetics over the complex-free anthocyanins

Astaxanthin – Anthocyanins: 8.5 fold improvement in pharmacokinetics over the complex-free anthocyanins

Lycopene – 50 mg phosphatidylcholine: improvement of lycopene pharmacokinetics by 8 fold in patients with coronary heart disease[46]

Lycopene – 450 mg phosphatidylcholine: improvement effective dose by 4 fold and liver span reduction in NAFLD patients[47]

Lycopene – DHA Omega 3: superior efficacy in blood triglyceride reduction with effective dose 8-16 fold lower than the complex-free DHA Omega 3, with additional LDL lowering effect[48]

Lutein – Zeaxanthin – DHA Omega 3:  8-10 fold improvement in pharmacokinetics[49]

Lycopene – Cacao Epicatechins – Dark chocolate lipids - co-crystallisation: 10 fold improvement in epicatechin pharmacokinetics[50]

Lutein – Cacao Epicatechins – Dark chocolate lipids - co-crystallisation[45]

Astaxanthin – Cacao Epicatechins – Dark chocolate lipids - co-crystallisation: 2.5-3.5 fold improvement in astaxanthin pharmacokinetics[51]

References

[edit]
  1. ^ a b Mezzomo, Natália; Ferreira, Sandra R. S. (2016-03-03). "Carotenoids Functionality, Sources, and Processing by Supercritical Technology: A Review". Journal of Chemistry. 2016: e3164312. doi:10.1155/2016/3164312. ISSN 2090-9063.
  2. ^ Hashimoto, Hideki; Uragami, Chiasa; Cogdell, Richard J. (2016). "Carotenoids and Photosynthesis". Carotenoids in Nature. Subcellular Biochemistry. Vol. 79. pp. 111–139. doi:10.1007/978-3-319-39126-7_4. ISBN 978-3-319-39124-3. ISSN 0306-0225. PMID 27485220.
  3. ^ Cogdell, Richard J.; Gardiner, Alastair T. (1993). "[18] Functions of carotenoids in photosynthesis". Carotenoids Part B: Metabolism, Genetics, and Biosynthesis. Methods in Enzymology. Vol. 214. Academic Press. pp. 185–193. doi:10.1016/0076-6879(93)14065-Q. ISBN 9780121821159.
  4. ^ Koca Bozalan, Nuray; Karadeniz, Feryal (2011). "Carotenoid Profile, Total Phenolic Content, and Antioxidant Activity of Carrots". International Journal of Food Properties. 14 (5): 1060–1068. doi:10.1080/10942910903580918. ISSN 1094-2912. S2CID 83976407.
  5. ^ Saini, Ramesh Kumar; Zamany, Ahmad Jawid; Keum, Young-Soo (2017). "Ripening improves the content of carotenoid, α-tocopherol, and polyunsaturated fatty acids in tomato (Solanum lycopersicum L.) fruits". 3 Biotech. 7 (1): 43. doi:10.1007/s13205-017-0666-0. ISSN 2190-572X. PMC 5428086. PMID 28444589.
  6. ^ Costantini, David; Dell'omo, Giacomo; Casagrande, Stefania; Fabiani, Anna; Carosi, Monica; Bertacche, Vittorio; Marquez, Cruz; Snell, Howard; Snell, Heidi; Tapia, Washington; Gentile, Gabriele (2005). "Inter-population variation of carotenoids in Galápagos land iguanas (Conolophus subcristatus)". Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology. 142 (2): 239–244. doi:10.1016/j.cbpb.2005.07.011. ISSN 1096-4959. PMID 16129639.
  7. ^ Teglia, CM; Attademo, AM; Peltzer, PM; Goicoechea, HC; Lajmanovich, RC (2015). "Plasma retinoids concentration in Leptodactylus chaquensis (Amphibia: Leptodactylidae) from rice agroecosystems". Chemosphere. 135: 24–30. doi:10.1016/j.chemosphere.2015.03.063. hdl:11336/135977. PMID 25880706.
  8. ^ Strzałka, K.; Kostecka-Gugała, A.; Latowski, D. (2003). "Carotenoids and Environmental Stress in Plants: Significance of Carotenoid-Mediated Modulation of Membrane Physical Properties". Russian Journal of Plant Physiology. 50 (2): 168–173. doi:10.1023/A:1022960828050. S2CID 5026106.
  9. ^ Llansola-Portoles, Manuel J.; Pascal, Andrew A.; Robert, Bruno (2017). "Electronic and vibrational properties of carotenoids: from in vitro to in vivo". Journal of the Royal Society Interface. 14 (135): 20170504. doi:10.1098/rsif.2017.0504. ISSN 1742-5689. PMC 5665833. PMID 29021162.
  10. ^ Zigangirova, Naylia A.; Morgunova, Elena Y.; Fedina, Elena D.; Shevyagina, Natalia V.; Borovaya, Tatiana G.; Zhukhovitsky, Vladimir G.; Kyle, Nigel H.; Petyaev, Ivan M. (2017). "Lycopene Inhibits Propagation of Chlamydia Infection". Scientifica. 2017: 1–11. doi:10.1155/2017/1478625. ISSN 2090-908X. PMC 5602621. PMID 28948060.
  11. ^ a b c d Petyaev, I. M.; Vuylsteke, A.; Bethune, D. W.; Hunt, J. V. (1998-01-01). "Plasma Oxygen during Cardiopulmonary Bypass: A Comparison of Blood Oxygen Levels with Oxygen Present in Plasma Lipid". Clinical Science. 94 (1): 35–41. doi:10.1042/cs0940035. ISSN 0143-5221. PMID 9505864.
  12. ^ a b Petyaev, Ivan M.; Dovgalevsky, Pavel Y.; Klochkov, Victor A.; Chalyk, Natalya E.; Kyle, Nigel (2012). "Whey Protein Lycosome Formulation Improves Vascular Functions and Plasma Lipids with Reduction of Markers of Inflammation and Oxidative Stress in Prehypertension". The Scientific World Journal. 2012: 269476. doi:10.1100/2012/269476. ISSN 1537-744X. PMC 3541600. PMID 23326213.
  13. ^ Meldrum, DR; Morris, MA; Gambone, JC (2017). "Obesity pandemic: causes, consequences, and solutions-but do we have the will?". Fertility and Sterility. 107 (4): 833–839. doi:10.1016/j.fertnstert.2017.02.104. PMID 28292617.
  14. ^ Blüher, Matthias (2019). "Obesity: global epidemiology and pathogenesis". Nature Reviews Endocrinology. 15 (5): 288–298. doi:10.1038/s41574-019-0176-8. ISSN 1759-5029. PMID 30814686. S2CID 71146382.
  15. ^ Petyaev, Ivan M.; Dovgalevsky, Pavel Y.; Chalyk, Natalia E.; Klochkov, Victor; Kyle, Nigel H. (2014). "Reduction in blood pressure and serum lipids by lycosome formulation of dark chocolate and lycopene in prehypertension". Food Science & Nutrition. 2 (6): 744–750. doi:10.1002/fsn3.169. ISSN 2048-7177. PMC 4256580. PMID 25493193.
  16. ^ Petyaev, Ivan M.; Chalyk, Natalia E.; Klochkov, Victor A.; Pristenskiy, Dmitry V.; Chernyshova, Marina P.; Kyle, Nigel H. (2019-05-16). "Ingestion of Lycosome L-tug Formulation of Dark Chocolate Ameliorates Postprandial Hyperlipidemia and Hyperglycemia in Healthy Volunteers". Advances in Preventive Medicine. 2019: 1–8. doi:10.1155/2019/1659384. ISSN 2090-3480. PMC 6541969. PMID 31223502. S2CID 181629305.
  17. ^ a b Petyaev, I (2019). "Hydrocarbon / lipid – carotenoid complexes". Archived from the original on 2021-01-15.
  18. ^ Olson, J. A. (1994-01-01). "Absorption, transport and metabolism of carotenoids in humans". Pure and Applied Chemistry. 66 (5): 1011–1016. doi:10.1351/pac199466051011. ISSN 1365-3075. S2CID 11371664.
  19. ^ Parker, Robert S. (1996). "Absorption, metabolism, and transport of carotenoids". The FASEB Journal. 10 (5): 542–551. doi:10.1096/fasebj.10.5.8621054. ISSN 0892-6638. PMID 8621054. S2CID 12189939.
  20. ^ Milde, Jens; Elstner, Erich F.; Graßmann, Johanna (2007). "Synergistic effects of phenolics and carotenoids on human low-density lipoprotein oxidation". Molecular Nutrition & Food Research. 51 (8): 956–961. doi:10.1002/mnfr.200600271. PMID 17639513.
  21. ^ Cocate, P. G.; Natali, A. J.; Alfenas, R. C. G.; de Oliveira, A.; dos Santos, E. C.; Hermsdorff, H. H. M. (2015-07-28). "Carotenoid consumption is related to lower lipid oxidation and DNA damage in middle-aged men". British Journal of Nutrition. 114 (2): 257–264. doi:10.1017/S0007114515001622. ISSN 0007-1145. PMID 26079483. S2CID 22406428.
  22. ^ Deming, D. M.; Erdman, John W. (1999-01-01). "Mammalian carotenoid absorption and metabolism". Pure and Applied Chemistry. 71 (12): 2213–2223. doi:10.1351/pac199971122213. ISSN 1365-3075. S2CID 27275029.
  23. ^ Shmarakov, Igor O.; Yuen, Jason J.; Blaner, William S. (2013), Tanumihardjo, Sherry A. (ed.), "Carotenoid Metabolism and Enzymology", Carotenoids and Human Health, Totowa, NJ: Humana Press, pp. 29–56, doi:10.1007/978-1-62703-203-2_3, ISBN 978-1-62703-202-5, retrieved 2021-02-27
  24. ^ Cole, Laura K.; Vance, Jean E.; Vance, Dennis E. (2012). "Phosphatidylcholine biosynthesis and lipoprotein metabolism". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1821 (5): 754–761. doi:10.1016/j.bbalip.2011.09.009. ISSN 1388-1981. PMID 21979151.
  25. ^ van der Veen, Jelske N.; Kennelly, John P.; Wan, Sereana; Vance, Jean E.; Vance, Dennis E.; Jacobs, René L. (2017). "The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease". Biochimica et Biophysica Acta (BBA) - Biomembranes. 1859 (9): 1558–1572. doi:10.1016/j.bbamem.2017.04.006. ISSN 0005-2736. PMID 28411170.
  26. ^ Spahis, Schohraya; Delvin, Edgard; Borys, Jean-Michel; Levy, Emile (2017). "Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis". Antioxidants & Redox Signaling. 26 (10): 519–541. doi:10.1089/ars.2016.6776. ISSN 1523-0864. PMID 27452109.
  27. ^ Mato, José M.; Alonso, Cristina; Noureddin, Mazen; Lu, Shelly C. (2019-06-28). "Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease". World Journal of Gastroenterology. 25 (24): 3009–3020. doi:10.3748/wjg.v25.i24.3009. ISSN 2219-2840. PMC 6603806. PMID 31293337.
  28. ^ Korytko, Peter J.; Rodvold, Keith A.; Crowell, James A.; Stacewicz-Sapuntzakis, Maria; Diwadkar-Navsariwala, Veda; Bowen, Phyllis E.; Schalch, Wolfgang; Levine, Barry S. (2003-09-01). "Pharmacokinetics and Tissue Distribution of Orally Administered Lycopene in Male Dogs". The Journal of Nutrition. 133 (9): 2788–2792. doi:10.1093/jn/133.9.2788. ISSN 0022-3166. PMID 12949366.
  29. ^ Holzapfel, Nina Pauline; Holzapfel, Boris Michael; Champ, Simon; Feldthusen, Jesper; Clements, Judith; Hutmacher, Dietmar Werner (2013-07-12). "The Potential Role of Lycopene for the Prevention and Therapy of Prostate Cancer: From Molecular Mechanisms to Clinical Evidence". International Journal of Molecular Sciences. 14 (7): 14620–14646. doi:10.3390/ijms140714620. ISSN 1422-0067. PMC 3742263. PMID 23857058.
  30. ^ Johnson, Elizabeth J.; Vishwanathan, Rohini; Johnson, Mary Ann; Hausman, Dorothy B.; Davey, Adam; Scott, Tammy M.; Green, Robert C.; Miller, L. Stephen; Gearing, Marla; Woodard, John; Nelson, Peter T. (2013). "Relationship between Serum and Brain Carotenoids, α-Tocopherol, and Retinol Concentrations and Cognitive Performance in the Oldest Old from the Georgia Centenarian Study". Journal of Aging Research. 2013: 951786. doi:10.1155/2013/951786. ISSN 2090-2204. PMC 3690640. PMID 23840953.
  31. ^ Schweigert, F. J. (2003-06-01). "Concentrations of carotenoids, retinol and alpha-tocopherol in plasma and follicular fluid of women undergoing IVF". Human Reproduction. 18 (6): 1259–1264. doi:10.1093/humrep/deg249. PMID 12773456.
  32. ^ Jackson, M. J. (1998-01-01). "Plasma Oxygen during Cardiopulmonary Bypass". Clinical Science. 94 (1): 1. doi:10.1042/cs0940001. ISSN 0143-5221. PMID 9505858.
  33. ^ Christakos, Sylvia; Dhawan, Puneet; Verstuyf, Annemieke; Verlinden, Lieve; Carmeliet, Geert (2016). "Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects". Physiological Reviews. 96 (1): 365–408. doi:10.1152/physrev.00014.2015. ISSN 0031-9333. PMC 4839493. PMID 26681795.
  34. ^ Vanherwegen, An-Sofie; Gysemans, Conny; Mathieu, Chantal (2017). "Regulation of Immune Function by Vitamin D and Its Use in Diseases of Immunity". Endocrinology and Metabolism Clinics of North America. 46 (4): 1061–1094. doi:10.1016/j.ecl.2017.07.010. ISSN 1558-4410. PMID 29080635.
  35. ^ Sassi, Francesca; Tamone, Cristina; D’Amelio, Patrizia (2018-11-03). "Vitamin D: Nutrient, Hormone, and Immunomodulator". Nutrients. 10 (11): 1656. doi:10.3390/nu10111656. ISSN 2072-6643. PMC 6266123. PMID 30400332.
  36. ^ Harris, Susan S.; Dawson-Hughes, Bess; Perrone, Gayle A. (1999). "Plasma 25-Hydroxyvitamin D Responses of Younger and Older Men to Three Weeks of Supplementation with 1800 IU/day of Vitamin D". Journal of the American College of Nutrition. 18 (5): 470–474. doi:10.1080/07315724.1999.10718885. ISSN 0731-5724. PMID 10511329.
  37. ^ Strange, Richard C; Shipman, Kate E; Ramachandran, Sudarshan (2015-07-10). "Metabolic syndrome: A review of the role of vitamin D in mediating susceptibility and outcome". World Journal of Diabetes. 6 (7): 896–911. doi:10.4239/wjd.v6.i7.896. ISSN 1948-9358. PMC 4499524. PMID 26185598.
  38. ^ Migliaccio, Silvia; Di Nisio, Andrea; Mele, Chiara; Scappaticcio, Lorenzo; Savastano, Silvia; Colao, Annamaria (2019). "Obesity and hypovitaminosis D: causality or casualty?". International Journal of Obesity Supplements. 9 (1): 20–31. doi:10.1038/s41367-019-0010-8. ISSN 2046-2166. PMC 6683181. PMID 31391922.
  39. ^ Wortsman, Jacobo; Matsuoka, Lois Y; Chen, Tai C; Lu, Zhiren; Holick, Michael F (2000-09-01). "Decreased bioavailability of vitamin D in obesity". The American Journal of Clinical Nutrition. 72 (3): 690–693. doi:10.1093/ajcn/72.3.690. ISSN 0002-9165. PMID 10966885.
  40. ^ Wikvall, K. (2001-02-01). "Cytochrome P450 enzymes in the bioactivation of vitamin D to its hormonal form (Review)". International Journal of Molecular Medicine. 7 (2): 201–9. doi:10.3892/ijmm.7.2.201. ISSN 1107-3756. PMID 11172626.
  41. ^ Yamamoto, Erin A.; Jørgensen, Trine N. (2020-01-21). "Relationships Between Vitamin D, Gut Microbiome, and Systemic Autoimmunity". Frontiers in Immunology. 10: 3141. doi:10.3389/fimmu.2019.03141. ISSN 1664-3224. PMC 6985452. PMID 32038645.
  42. ^ Wiese, Maria; Bashmakov, Yuriy; Chalyk, Natalia; Nielsen, Dennis Sandris; Krych, Łukasz; Kot, Witold; Klochkov, Victor; Pristensky, Dmitry; Bandaletova, Tatyana; Chernyshova, Marina; Kyle, Nigel (2019-06-02). "Prebiotic Effect of Lycopene and Dark Chocolate on Gut Microbiome with Systemic Changes in Liver Metabolism, Skeletal Muscles and Skin in Moderately Obese Persons". BioMed Research International. 2019: 1–15. doi:10.1155/2019/4625279. ISSN 2314-6133. PMC 6604498. PMID 31317029.
  43. ^ a b Bashmakov, Yuriy K.; Assaad-Khalil, Samir H.; Abou Seif, Myriam; Udumyan, Ruzan; Megallaa, Magdy; Rohoma, Kamel H.; Zeitoun, Mohamed; Petyaev, Ivan M. (2014-02-20). "Resveratrol Promotes Foot Ulcer Size Reduction in Type 2 Diabetes Patients". ISRN Endocrinology. 2014: 816307. doi:10.1155/2014/816307. ISSN 2090-4649. PMC 3950537. PMID 24701359.
  44. ^ "Project Information - NIH RePORTER - NIH Research Portfolio Online Reporting Tools Expenditures and Results". projectreporter.nih.gov. Retrieved 2021-02-27.
  45. ^ Petyaev, Ivan M. (2015). "State of the art paper Improvement of hepatic bioavailability as a new step for the future of statin". Archives of Medical Science. 2 (2): 406–410. doi:10.5114/aoms.2015.50972. ISSN 1734-1922. PMC 4424257. PMID 25995759.
  46. ^ Petyaev, Ivan M.; Dovgalevsky, Pavel Y.; Klochkov, Victor A.; Chalyk, Natalya E.; Pristensky, Dmitry V.; Chernyshova, Marina P.; Udumyan, Ruzan; Kocharyan, Taron; Kyle, Nigel H.; Lozbiakova, Marina V.; Bashmakov, Yuriy K. (2018). "Effect of lycopene supplementation on cardiovascular parameters and markers of inflammation and oxidation in patients with coronary vascular disease". Food Science & Nutrition. 6 (6): 1770–1777. doi:10.1002/fsn3.734. PMC 6145244. PMID 30258622.
  47. ^ Petyaev, Ivan M.; Dovgalevsky, Pavel Y.; Chalyk, Natalia E.; Klochkov, Victor A.; Kyle, Nigel H.; Bashmakov, Yuriy K. (2018). "Reduction of Liver Span and Parameters of Inflammation in Nonalcoholic Fatty Liver Disease Patients Treated with Lycosome Formulation of Phosphatidylcholine: A Preliminary Report". International Journal of Chronic Diseases. 2018: 1–7. doi:10.1155/2018/4549614. ISSN 2356-6981. PMC 5899869. PMID 29805971.
  48. ^ Petyaev, Ivan M.; Dovgalevsky, Pavel Y.; Chalyk, Natalia E.; Klochkov, Victor A.; Kyle, Nigel H. (2019). "Reduction of elevated lipids and low-density lipoprotein oxidation in serum of individuals with subclinical hypoxia and oxidative stress supplemented with lycosome formulation of docosahexaenoic acid". Food Science & Nutrition. 7 (4): 1147–1156. doi:10.1002/fsn3.784. ISSN 2048-7177. PMC 6475726. PMID 31024687. S2CID 108777776.
  49. ^ Petyaev, IvanM; Chalyk, NatalyaE; Klochkov, VictorA; Pristensky, DmitryV; Chernyshova, MarinaP; Kyle, NigelH; Bashmakov, YuriyK (2018). "Pharmacokinetics and oxidation parameters in volunteers supplemented with microencapsulated docosahexaenoic acid". International Journal of Applied and Basic Medical Research. 8 (3): 148–154. doi:10.4103/ijabmr.IJABMR_367_17. ISSN 2229-516X. PMC 6082003. PMID 30123743.
  50. ^ Petyaev, Ivan M.; Chalyk, Natalia E.; Klochkov, Victor A.; Pristenskiy, Dmitry V.; Chernyshova, Marina P.; Kyle, Nigel H. (2016). "Ingestion of Lycosome L-tug Formulation of Dark Chocolate Ameliorates Postprandial Hyperlipidemia and Hyperglycemia in Healthy Volunteers". American Journal of Food Science and Nutrition. 3 (3): 37–44. doi:10.1155/2019/1659384. ISSN 2090-3480. PMC 6541969. PMID 31223502.
  51. ^ Petyaev, Ivan M.; Klochkov, V. A.; Chalyk, N. E.; Pristensky, D. V.; Chernyshova, M. P.; Kyle, N. H; Bashmakov, Y. K. (2018). "Markers of Hypoxia and Oxidative Stress in Aging Volunteers Ingesting Lycosomal Formulation of Dark Chocolate Containing Astaxanthin". The Journal of Nutrition, Health & Aging. 22 (9): 1092–1098. doi:10.1007/s12603-018-1063-z. ISSN 1279-7707. PMID 30379308. S2CID 53108737.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Carotenoid_complex&oldid=1229507719"